Jeremy Davis
Professor and Chief, Division of Surgical Oncology
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Jeremy Davis is a Professor and Chief of the Division of Surgical Oncology at the University of Maryland School of Medicine, USA. His research focuses on various aspects of gastric cancer, hereditary diffuse gastric cancer, and the impacts of surgical interventions in oncology. Recent publications include studies on cytoreduction and HIPEC, cancer surveillance strategies, and the role of micronutrient supplementation in postoperative care for patients with genetic variants.
Articles (18)
Extent of IMPACT CpG island promoter methylation in mouse cell lines (KPC, 4964-POP, and 4964-HOP), and five human pancreatic liver metastases compared to three primary PDACs, and two normal pancreas and liver tissue.
Year:
2025
List of all hits identified in the cDNA screen and categorized by function. cDNAs highlighted in red were identified in the 3 KB library fraction. The number of tumor lesions identifying the cDNA is given.
Year:
2025
Given the propensity of aggressive epithelial tumors to form hepatic metastases, we performed an in vivo cDNA screen using the mouse liver and KRAS G12D / TP53 R273H pancreatic cells that identified the RNA-binding protein GCN1 as an integral component of hepatic outgrowth. RNAi experiments reveal that GCN1 triggers the integrated stress response (ISR) to activate serine, folate, and methionine biosynthetic pathways together with amino acid transporters, which act in concert to facilitate acquisition of metabolites and to restore redox homeostasis. Alongside the activation of the ISR, we found that GCN1 also functions in the nucleus where it interacts with HNRNPK to suppress the expression of MHC-I molecules and NK ligands. Intriguingly, we identified IMPACT as an endogenous competitive inhibitor of GCN1 that blocks both ISR-dependent metabolic control and disrupts HNRNPK interaction. In doing so, IMPACT enhances tumor immunogenicity to unleash NK cell killing, in addition to sensitizing metastatic tumor cells to immune checkpoint blockade. Significance: Metastatic tumor cells display profound immunometabolic plasticity to colonize distant organs. We identify IMPACT, an inhibitor of GCN1-stress signaling, expression of which curtailed metabolic plasticity and augmented tumor immunogenicity, sensitizing metastatic tumor cells to NK cell–mediated destruction.
Year:
2025
Background Pathogenic or likely pathogenic (P/LP) CDH1 germline genetic variants are causally linked to early onset diffuse gastric cancer and prophylactic total gastrectomy (PTG) is a recommended intervention for (P/LP) CDH1 variant carriers. However, PTG introduces fundamental challenges to a patient's quality of life (QOL) and psychological well‐being. There is a growing need for evidence‐based recommendations to address the psychosocial needs of PTG patients. The present review summarizes published literature on psychosocial sequelae and quality of life reported post‐PTG in germline (P/LP) CDH1 variant carriers. Methods Articles were extracted from the PubMed database using the following search terms: “total gastrectomy”, “CDH1”, “CTNNA1”, “guidelines”, “psychological”, “psychiatric”, “mental health”, “quality of life”, and “longitudinal”. Articles that address psychological and QOL implications and outcomes for PTG or total gastrectomy (TG) patients were included. Articles that mentioned “psychosocial factors” generally, without specific details, were excluded. Results 37 articles met inclusion criteria. Seven of the most frequently mentioned psychosocial domains in the published literature include quality of life ( n = 22), social relationships ( n = 12), depression and anxiety ( n = 8), decision‐making ( n = 7), employment and finances ( n = 4), body image ( n = 5), and substance abuse ( n = 3). Conclusions Considering the known psychological impact of a genetic cancer predisposition diagnosis and the significant postoperative lifestyle adjustment, this review identifies a need for standardized integration of mental health care along the PTG surgical continuum. The combination of the diagnosis of a hereditary cancer syndrome and the life‐altering nature of prophylactic total gastrectomy (PTG) presents a psychosocial vulnerability for CDH1 (P/LP) variant carriers.
Year:
2025
Germline CDH1 loss-of-function mutations are causally linked to an increased lifetime risk of diffuse gastric cancer (DGC). Early, multifocal signet ring cell (SRC) lesions are ubiquitous among CDH1 variant carriers, yet only a subset of patients will develop advanced DGC. A multiomic analysis was performed to establish the molecular phenotype of early SRC lesions and how they differ from advanced DGC using 20 samples from human total gastrectomy specimens of germline CDH1 variant carriers. Spatial transcriptomic analysis demonstrated reduced CDH1 gene expression and increased expression of extracellular matrix remodeling in SRC lesions compared with unaffected adjacent gastric epithelium. Single-cell RNA sequencing revealed an SRC-enriched signature with markers REG1A , VIM , AQP5 , PRR4 , MUC6 , and AGR2 . Importantly, SRC lesions lacked alterations in known drivers of gastric cancer ( TP53 , ARID1A , and KRAS ) and activation of associated signal transduction pathways. Advanced DGC demonstrated E-cadherin reexpression, somatic TP53 and ERBB3 mutations, and upregulated CTNNA1 , MYC , and MET expression when compared with SRC lesions. Implications: The marked differences in the genomic and transcriptomic profiles of SRC lesions and advanced DGC support the consideration of SRC lesions as precancers in patients with germline CDH1 mutations.
Year:
2025
Background Diagnosis of a hereditary cancer syndrome may impact family planning, particularly in reproductive age individuals. Factors influencing reproductive decision-making are understudied in individuals with germline CDH1 pathogenic or likely pathogenic (P/LP) variants. Methods We characterised reproductive decision-making and perinatal outcomes in 121 individuals aged 18–49 with hereditary diffuse gastric and lobular breast cancer syndrome due to a germline CDH1 P/LP variant. Results Half of individuals (50%, 60/121) reported their CDH1 diagnosis impacted family planning. Psychosocial and economic barriers to reproduction were encountered by 47% (56/119) of patients. Additionally, 12% (15/121) of individuals delayed pregnancy to prioritise personal cancer risk management with either endoscopic surveillance, prophylactic total gastrectomy (PTG) or mastectomy. Women were more likely to experience guilt about passing their CDH1 variant to offspring compared with men. Perinatal and fetal outcomes were investigated in six women who gave birth at a median time of 24 months (IQR 20–44) after PTG. Maternal micronutrient deficiencies were not uncommon in pregnant women after PTG despite compliance with a bariatric, prenatal multivitamin. Majority of women who became pregnant after PTG reported worsening post-gastrectomy syndromes. Most infants (90%, 9/10) born after PTG were full-term and no fetal complications were reported. Conclusion Reproductive decision-making is complex in individuals with germline CDH1 variants, who often encounter psychosocial and physical challenges during family planning and pregnancy. However, successful pregnancy is possible after PTG with the guidance of a multidisciplinary team including maternal fetal medicine specialists and a registered dietitian. Trial registration number NCT03030404 .
Year:
2025
There is a high unmet need for early detection approaches for diffuse gastric cancer (DGC). We examined whether the stool proteome of mouse models of gastric cancer (GC) and individuals with hereditary diffuse gastric cancer (HDGC) have utility as biomarkers for early detection. Proteomic mass spectrometry of the stool of a genetically engineered mouse model driven by oncogenic KrasG12D and loss of p53 and Cdh1 in gastric parietal cells [known as Triple Conditional (TCON) mice] identified differentially abundant proteins compared with littermate controls. Immunoblot assays validated a panel of proteins, including actinin alpha 4 (ACTN4), N-acylsphingosine amidohydrolase 2 (ASAH2), dipeptidyl peptidase 4 (DPP4), and valosin-containing protein (VCP), as enriched in TCON stool compared with littermate control stool. Immunofluorescence analysis of these proteins in TCON stomach sections revealed increased protein expression compared with littermate controls. Proteomic mass spectrometry of stool obtained from patients with HDGC with CDH1 mutations identified increased expression of ASAH2, DPP4, VCP, lactotransferrin (LTF), and tropomyosin-2 relative to stool from healthy sex- and age-matched donors. Chemical inhibition of ASAH2 using C6 urea ceramide was toxic to GC cell lines and GC patient-derived organoids. This toxicity was reversed by adding downstream products of the S1P synthesis pathway, which suggested a dependency on ASAH2 activity in GC. An exploratory analysis of the HDGC stool microbiome identified features that correlated with patient tumors. Herein, we provide evidence supporting the potential of analyzing stool biomarkers for the early detection of DGC. Prevention Relevance: This study highlights a novel panel of stool protein biomarkers that correlate with the presence of DGC and has potential use as early detection to improve clinical outcomes.
Year:
2024
There is a high unmet need for early detection approaches for diffuse gastric cancer (DGC). We examined whether the stool proteome of mouse models of gastric cancer (GC) and individuals with hereditary diffuse gastric cancer (HDGC) have utility as biomarkers for early detection. Proteomic mass spectrometry of the stool of a genetically engineered mouse model driven by oncogenic KrasG12D and loss of p53 and Cdh1 in gastric parietal cells [known as Triple Conditional (TCON) mice] identified differentially abundant proteins compared with littermate controls. Immunoblot assays validated a panel of proteins, including actinin alpha 4 (ACTN4), N-acylsphingosine amidohydrolase 2 (ASAH2), dipeptidyl peptidase 4 (DPP4), and valosin-containing protein (VCP), as enriched in TCON stool compared with littermate control stool. Immunofluorescence analysis of these proteins in TCON stomach sections revealed increased protein expression compared with littermate controls. Proteomic mass spectrometry of stool obtained from patients with HDGC with CDH1 mutations identified increased expression of ASAH2, DPP4, VCP, lactotransferrin (LTF), and tropomyosin-2 relative to stool from healthy sex- and age-matched donors. Chemical inhibition of ASAH2 using C6 urea ceramide was toxic to GC cell lines and GC patient-derived organoids. This toxicity was reversed by adding downstream products of the S1P synthesis pathway, which suggested a dependency on ASAH2 activity in GC. An exploratory analysis of the HDGC stool microbiome identified features that correlated with patient tumors. Herein, we provide evidence supporting the potential of analyzing stool biomarkers for the early detection of DGC. Prevention Relevance: This study highlights a novel panel of stool protein biomarkers that correlate with the presence of DGC and has potential use as early detection to improve clinical outcomes.
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Collaborators (22)
Todd Prickett
Staff Scientist
National Institutes of Health
Samuel Klempner
Associate Professor
Massachusetts General Hospital
Hyuk Lee
Sungkyunkwan University School of Medicine
Pankaj Singh
Professor and Chair
University of Oklahoma Health Sciences Center
Markku Miettinen
Senior Clinician, Head of Surgical Pathology
National Institutes of Health
Irene Gullo
Professor Auxiliar Convidado
University of Porto
David Drew
Assistant Professor of Medicine
Massachusetts General Hospital
Kirsten Remmert
Staff Scientist
National Institutes of Health
Sandra Ryeom
Associate Professor/Associate Dean
Columbia University Irving Medical Center
Marina Pasca Di Magliano
Associate Professor
University of Michigan
Alexander Rossi
Assistant Professor
Yale University
Margaret Cam
Staff Scientist
National Institutes of Health
Rodrigo Xavier das Neves
Research Assistant Professor
University of Pittsburgh
James Yang
National Cancer Institute
Carolina Larrain
NYU Langone Health
Reed Ayabe
Assistant Professor
University of California Irvine Medical Center
Liqiang Xi
Staff Scientist
National Institutes of Health
Jeeyun Lee
Samsung Medical Center
Harris Wang
Professor
Columbia University
Theo Heller
National Institutes of Health
Costas A. Lyssiotis
University of Michigan
sivasish sindiri
National Cancer Institute
Make your next move.
Prepare your application
Review drafts before you send them.